EBITDA: Income before interest, taxes, depreciation and amortization.
COSCIENS Biopharma Inc. (CSCI) had EBITDA of $-2.15M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$2.75M |
|
$-2.70M |
|
$1.77M |
|
$0.97M |
|
$5.10M |
|
$-2.35M |
|
$-0.35M |
|
$-2.70M |
|
$-2.70M |
|
$-2.70M |
|
$-2.70M |
|
$-2.70M |
|
$-2.70M |
|
$-2.35M |
|
|
EBITDA |
$-2.15M |
3.17M |
|
3.17M |
|
$-0.85 |
|
$-0.85 |
|
| Balance Sheet Financials | |
$16.50M |
|
$10.92M |
|
$11.05M |
|
$27.56M |
|
$5.53M |
|
-- |
|
$14.93M |
|
$20.46M |
|
$7.10M |
|
$7.10M |
|
$7.10M |
|
3.17M |
|
| Cash Flow Statement Financials | |
$-6.33M |
|
$-0.66M |
|
$-0.31M |
|
$16.39M |
|
$9.33M |
|
$-7.06M |
|
$-0.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
35.43% |
|
-85.59% |
|
-85.59% |
|
-- |
|
-98.22% |
|
-98.25% |
|
$-6.99M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.97 |
|
0.99 |
|
91.11 |
|
-38.06% |
|
-38.06% |
|
-9.80% |
|
-38.06% |
|
$2.24 |
|
$-2.20 |
|
$-1.99 |
|